HealthInvest April 2025

Following the success of our inaugural event in September 2024, and with strong investor interest driving momentum in the healthcare sector, HealthInvest returns to showcase some of Australia’s leading and emerging health and life sciences companies to an audience of professional and retail investors.

Morgans, IR Department and Stockhead have partnered again to bring together five innovative healthcare companies, providing investors with this unique opportunity to hear about some of the latest innovations shaping the future of healthcare and life sciences investment.

Presenting companies and speakers include:

• Dimerix Ltd (ASX: DXB) – Nina Webster, CEO and Managing Director
• EMVision Medical Devices Limited (ASX: EMV) – Scott Kirkland, CEO and Managing Director
• Microba Life Sciences Limited (ASX: MAP) – Dr Luke Reid, Chief Executive Officer
• Lumos Diagnostics Holdings Ltd (ASX: LDX) – Doug Ward, CEO and Managing Director
• Orthocell Ltd (ASX: OCC) – Paul Anderson, CEO and Managing Director

 

 

 

 

 

Below we delve into the focus area for each company and how they are making strides in their healthcare fields.

Dimerix (ASX: DXB)

A clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focussed on developing its proprietary Phase 3 product candidate DMX-200 (QYTOVRA® in some territories), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for respiratory disease. DMX-200 and DMX-700 were both identified using Dimerix’ proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

EMVision Medical Devices Limited (ASX: EMV)

An innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neurodiagnostic devices. Our vision is to help transform and improve the timely diagnosis of stroke and other time sensitive medical emergencies, at the point-of-care.

Microba Life Sciences (ASX: MAP)

A company at the forefront of microbiome diagnostics & therapeutics and are on a mission to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. 

Lumos Diagnostics Ltd (ASX: LDX)

Lumos specialises in rapid and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for the POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

Orthocell Ltd (ASX: OCC)

A regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include CelGro^TM platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+^TM was the first product approved for dental GBR applications, and is distributed globally by BioHorizons Implant Systems Inc. Striate+^TM is cleared for use in the US (510k), Canada (MDL), Australia (ARTG), New Zealand (WAND), the UK (UKCA Mark) and Europe (CE Mark). Remplir ^TM, for peripheral nerve reconstruction, recently received approval in Australia, New Zealand and Singapore and is distributed exclusively by Device Technologies. SmrtGraft ^TM, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company’s other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

Join us at our 2 April HealthInvest summit

Whether you're a professional or retail investor, we invite you to join us at HealthInvest to gain insights into the cutting-edge developments shaping the future of healthcare.

If you'd like to be part of this exciting event, please click below:

register for free here.